More than 600,000 bottles of ramipril, a widely used blood pressure medication, were recalled across the U.S. after the FDA found that some ingredients came from an unapproved, uninspected facility in India.
Ramipril is an ACE inhibitor taken by over 2.4 million Americans each year to control blood pressure and lower the risk of heart attack, stroke, and kidney damage, making the recall a nationwide concern.
The recall affects Lupin Pharmaceuticals’ ramipril capsules in 2.5 mg, 5 mg, and 10 mg strengths, packaged in bottles of 90, 100, or 500 capsules with expiration dates through July 2026 and distributed to pharmacies and hospitals.
The FDA said the recall is precautionary because uninspected facilities may not meet safety and quality standards, though no adverse health events have been reported so far.
Patients should not stop ramipril suddenly; instead, they should check their bottle details and contact their pharmacist or healthcare provider if their medication matches the recalled lots.
Pharmacies may provide replacements, and doctors can prescribe alternatives like lisinopril or enalapril if needed, while the recall underscores the importance of strict global oversight to keep medicines safe.
